We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Microchip Biotechnologies Selected for Participation in the US Army Commercialization Pilot Program
News

Microchip Biotechnologies Selected for Participation in the US Army Commercialization Pilot Program

Microchip Biotechnologies Selected for Participation in the US Army Commercialization Pilot Program
News

Microchip Biotechnologies Selected for Participation in the US Army Commercialization Pilot Program

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Microchip Biotechnologies Selected for Participation in the US Army Commercialization Pilot Program"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Microchip Biotechnologies, Inc. (MBI) has been selected for participation in the inaugural US Army Commercialization Pilot Program. The Commercialization Pilot Program is a new program to identify SBIR firms that have Phase II projects with high transition potential to commercial products that meet high priority Army requirements.

MBI was identified as one of 25 firms selected out of 529 eligible firms and 416 applicants. MBI has been developing a biothreat detection system under Army SBIR funding.

"The acceptance of MBI by the Army to participate in the CPP is a further validation of our commitment to develop and commercialize microfluidic technologies for the protection of the combat troops and civilian populations," said Dr. Stevan Jovanovich, President and CEO of MBI.

Advertisement